ArticleMusculoskeletal care2025
Trends in Drug Claims for Non-Specific Low Back Pain in Québec, 1997 to 2018.
Article in Musculoskeletal care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Changes in pharmacological management of low back pain: Real-world evidence from a 4-year comparison (2021-2025).Northern clinics of Istanbul · 2026Article
- The impact of opioid prescribing guidelines on opioid dispensation: A systematic review and meta-analysis.Canadian journal of pain = Revue canadienne de la douleur · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThe aim of this study was to describe temporal trend of drugs claims after an episode of non-specific low back pain in Québec between 1997 and 2018, by pharmacological class.
methodsData came from the PROspective Québec study on work and health (PROQ), the Régie de l'assurance maladie du Québec (RAMQ) and Québec hospital services (Med-Echo). RAMQ common denomination codes were used to identify the types of medication claimed for an episode of non-specific low back pain. Multivariate log-binomial regression models were used to evaluate temporal trends in claims for the main pharmacological classes, taking into account dependence between multiple episodes.
resultsA total of 5214 episodes of non-specific low back pain were identified in 1658 people between 1997 and 2018. The mean age at the first medical service for low back pain was 64.1 years (standard deviation: 8.3 years). Results show a significant increase in opioid claims between 1997 and 1998 (4.1%) and 2009-2010 (12.7%) (p for trend = 0.0008), anticonvulsants between 1997 and 1998 (0.0%) and 2011-2012 (10.5%) (p for trend = 0.0002), and myorelaxants between 1997 and 1998 (2.0%) and 2009-2010 (8.8%) (p for trend < 0.0001), but no significant change in claims for antidepressants between 1997 and 1998 (0.5%) and 2016-2017 (2.6%) (p for trend = 0.5508).
conclusionClaims for opioids, anticonvulsants and myorelaxants for non-specific low back pain showed significant upward changes between 1997 and 2018 in Québec, in contrast to antidepressants. These temporal variations in claims were different for each group of drugs, with a greater variation for anticonvulsants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.